List of Xadago drug patents

Xadago is owned by Mdd Us.

Xadago contains Safinamide Mesylate.

Xadago has a total of 3 drug patents out of which 0 drug patents have expired.

Xadago was authorised for market use on 21 March, 2017.

Xadago is available in tablet;oral dosage forms.

Xadago can be used as adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes.

Drug patent challenges can be filed against Xadago from March, 2021.

The generics of Xadago are possible to be released after 21 March, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8278485 MDD US Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides
Jun, 2027

(4 years from now)

US8076515 MDD US Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8283380 MDD US Methods for treatment of parkinson's disease
Mar, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 21, 2022

Drugs and Companies using SAFINAMIDE MESYLATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 21 March, 2017

Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in